Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK/PD of HRS-7450 in Healthy Subjects
NCT06087094Phase 1Not yet recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of HRS-7450 in ischemic stroke (5 cohorts), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Adverse Events (AEs) at 8 days, Physical examination at 2 days and 2 more. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
HRS-7450
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06087094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087094.